Key Takeaways & Executive Findings
- •• Organoids recapitulate key aspects of human organ physiology, offering superior models for drug screening compared to 2D cultures. • Advanced 3D culture techniques, including bioprinting and microfluidics, enhance organoid complexity and maturation. • Integration of organoids with CRISPR and high-throughput screening accelerates drug discovery and personalized medicine. • Overcoming challenges like vascularization and reproducibility is crucial for translating organoid technology to clinical applications.
Abstract
Organoid technology has emerged as a powerful tool for modeling human development and disease, offering a more physiologically relevant platform than traditional two-dimensional cell cultures. This review provides a comprehensive overview of the development of three-dimensional (3D) cell culture techniques for organoids, highlighting advances in scaffold-based and scaffold-free methods, bioprinting, and microfluidic systems. We discuss the critical role of the extracellular matrix (ECM) and biochemical cues in guiding organoid self-organization and maturation. Furthermore, we explore the application of organoids in drug screening, emphasizing their potential to predict drug efficacy and toxicity with higher accuracy. Challenges such as reproducibility, scalability, and vascularization are addressed, along with future directions for integrating organoids with cutting-edge technologies like CRISPR and microfluidics to enhance their translational value.
1. Introduction
Organoids are three-dimensional (3D) cell cultures that mimic the architecture and function of native organs, derived from pluripotent stem cells or adult stem cells. They have revolutionized biomedical research by providing a more physiologically relevant platform than conventional two-dimensional (2D) monolayers. The development of organoid technology has been driven by advances in stem cell biology, extracellular matrix (ECM) engineering, and tissue culture techniques. These miniature organs recapitulate key aspects of organ development and disease, enabling researchers to study human biology in unprecedented detail.
Despite their promise, organoid culture faces significant challenges, including batch-to-batch variability, limited scalability, and lack of vascularization, which restrict their use in high-throughput drug screening and regenerative medicine. Recent innovations in bioprinting, microfluidics, and synthetic hydrogels have addressed some of these limitations, allowing for more controlled and reproducible organoid generation. Moreover, the integration of organoids with gene editing tools like CRISPR and advanced imaging techniques has expanded their utility in disease modeling and drug discovery.
This review aims to provide a comprehensive overview of the current state of 3D cell culture technology for organoids, focusing on the methods used to generate and mature organoids, the role of the ECM, and the application of organoids in drug screening. We also discuss the challenges and future perspectives, highlighting how organoid technology can be harnessed to accelerate precision medicine and reduce reliance on animal models.
Loading authentic research manuscript (Pages 1–5)...
Y. Zhang, L. Wang, X. Li, H. Chen (2026). Development of Three-Dimensional Cell Culture Technology for Organoids and Its Application in Drug Screening. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What are organoids and why are they important?
Organoids are miniature, three-dimensional organ-like structures grown in vitro from stem cells. They mimic the architecture and function of real organs, making them valuable for studying development, disease modeling, and drug testing with higher physiological relevance than traditional 2D cultures.
How are organoids generated?
Organoids are typically generated by embedding stem cells in a 3D extracellular matrix (e.g., Matrigel) and providing specific growth factors that guide self-organization and differentiation. Techniques such as bioprinting and microfluidic devices are increasingly used to enhance reproducibility and complexity.
What are the main challenges in organoid culture?
Key challenges include batch-to-batch variability, limited scalability, lack of vascularization, and incomplete maturation. These issues hinder their use in high-throughput screening and clinical applications. Ongoing research aims to overcome these by developing standardized protocols and integrating vascular networks.
How are organoids used in drug screening?
Organoids can be used to test drug efficacy and toxicity on human tissues, providing a more accurate prediction of patient responses. They enable personalized medicine by allowing testing on patient-derived organoids, and they reduce reliance on animal models.
What is the future of organoid technology?
The future involves integrating organoids with advanced technologies like CRISPR gene editing, microfluidics, and high-content imaging to create more complex and functional models. This will enhance their translational value in drug discovery, regenerative medicine, and precision oncology.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.